权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Alignment of Synthesis, Medicinal Chemistry and Structural Genomics to Accelerate UK Drug Discovery: Network SMS-Drug

合成、药物化学和结构基因组学的结合加速英国药物发现：网络短信药物

基本信息

批准号：
EP/I037229/1
负责人：
Nicholas Tomkinson
金额：
$ 23.46万
依托单位：
University of Strathclyde
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2011
资助国家：
英国
起止时间：
2011 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=EP%2FI037229%2F1
关键词：
Alignment Synthesis Medicinal Chemistry Structural

项目摘要

This programme will establish an Academia-Users Network in Chemical Biology to initiate, establish and nurture collaborative projects for the advancement of the drug discovery process. It aims to expand the capability of UK drug discovery, with new drug targets, new tools to validate targets and new multidisciplinary partnerships to explore the platforms, tools and targets of the future.In the post-genomic age opportunities for the development of new clinically validated targets for drug discovery and ultimately medicines are considerable. Drug discovery resources in academia and industry are not used efficiently, to the detriment of industry and society. Duplication could be reduced, and productivity could be increased, by performing basic biology and clinical proofs of concept within open access industry-academia partnerships.The major obstacle to clinical validation of new drug targets and the invention of new medicines is the availability and efficient delivery of small-molecules probes in order to understand the basic biology. Provision of these probes will allow for pre-clinical validation of drug targets and reduce the duplication of efforts across the pharmaceutical industry. Failures of potential drug molecules in late stage clinical trials result in enormous cost to the companies involved, the pharmaceutical industry in general and also dashes the hopes of countless patients.A relatively poor understanding of disease mechanisms, particularly in humans, confounds the drug discovery process and represents a pivotal area of biological research. Potent, selective and cell-permeable chemical probes are valued reagents in both fundamental and applied biological research, and they are essential for preclinical target validation in academic and industrial laboratories.Strategic alignment of academic synthetic chemists, molecular modellers and structural biologists with industrial end users will provide a blueprint for the provision of open access chemical probes to support clinical validation and drug discovery efforts within the UK.

该计划将建立一个化学生物学学术界用户网络，以启动，建立和培育合作项目，促进药物发现过程。它旨在扩大英国药物发现的能力，新的药物靶点，新的工具来验证目标和新的多学科合作伙伴关系，以探索未来的平台，工具和targets.In后基因组时代的机会，为药物发现和最终药物开发新的临床验证的目标是相当大的。学术界和工业界的药物发现资源没有得到有效利用，对工业和社会造成了损害。通过在开放获取的产业-学术界合作伙伴关系中进行基础生物学和临床概念验证，可以减少重复，提高生产率。新药靶点临床验证和新药发明的主要障碍是小分子探针的可用性和有效递送，以了解基础生物学。提供这些探针将允许药物靶点的临床前验证，并减少整个制药行业的重复工作。潜在药物分子在后期临床试验中的失败给相关公司和整个制药行业带来了巨大的成本，也使无数患者的希望破灭。对疾病机制（特别是人类疾病机制）的相对贫乏的理解混淆了药物发现过程，代表了生物学研究的一个关键领域。有效、选择性和细胞可渗透的化学探针在基础和应用生物学研究中都是有价值的试剂，它们对于学术和工业实验室的临床前靶标验证至关重要。分子建模人员和结构生物学家以及工业终端用户将为提供开放获取化学探针提供蓝图，以支持临床验证和药物发现工作在英国境内。